Search
  • Our Company
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    • Pipeline
    • NASH
    • IBD
    • Publications
  • Patients
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
      • Governance Documents
      • Committee Composition
    • Financials & Filings
      • Sec Filings
    • Investor Resources
      • Email Alerts
      • IR Contact
      • FAQs
  • News
  • Careers
  • Contact

Developing differentiated therapies that can improve the health of patients with liver and gastrointestinal (GI) diseases

NASH is expected to become the leading cause for liver transplants in the United States.

Inflammatory bowel disease is increasing in prevalence worldwide

Metacrine is building a pipeline of potential best-in-class FXR agonist therapeuties for NASH and other GI diseases

Our Company

We are a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and GI diseases.

Latest News

April 05, 2021

Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors


March 18, 2021

Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

September 2, 2020

Metacrine Strengthens Leadership Team with Key Appointments


August 27, 2020

Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients at the Digital International Liver Congress™ 2020

Programs

Our most advanced program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases.

© 2021 Metacrine   |   3985 Sorrento Valley Blvd., Suite C, San Diego, CA 92121
  • Our Company
    ▼
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    ▼
    • Pipeline
    • NASH
    • IBD
    • Publications
  • Patients
  • Investors
    ▼
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
      ▼
      • Governance Documents
      • Committee Composition
    • Financials & Filings
      ▼
      • Sec Filings
    • Investor Resources
      ▼
      • Email Alerts
      • IR Contact
      • FAQs
  • News
  • Careers
  • Contact